---
title: "Cretostimogene grenadenorepvec (CG0070) in BCG-unresponsive high-risk non-muscle-invasive bladder cancer: BOND"
description: "Formulary evidence on Cretostimogene grenadenorepvec (CG0070) in BCG-unresponsive high-risk non-muscle-invasive bladder cancer: BOND. Covers Objective, Location and study date, Study design, Eligibility criteria, Treatment, Study outcomes, and 3 further headings. 17 evidence topics quoted from 2 sources."
canonical: "https://www.evicenter.com/drugs/cretostimogene-grenadenorepvec--bcg-unresponsive-high-risk-non-muscle-invasive-bladder-cancer/clinical-evidence/bond"
published: "2026-11-18T10:43:03-05:00"
modified: "2026-11-18T10:43:03-05:00"
---

# Cretostimogene grenadenorepvec (CG0070) in BCG-unresponsive high-risk non-muscle-invasive bladder cancer: BOND

<a id="heading-3.1.5"></a>

## 3.1.5 BOND

<a id="heading-3.1.5.1"></a>

### 3.1.5.1 Objective

<a id="topic-3.1.5.1-1"></a>

#### Registered study purpose

> “It forms the hypothesis that this regimen may be used for people who have failed current forms of treatment and are recommended for cystectomy.”
> “It is with hope that this novel therapy will be able to delay or potentially avoid cystectomy for this patient population.”
> “This opportunity allows a study on the CG0070's beneficial effects, if any, on the standard of care for carcinoma in situ non muscle invasive bladder cancer patients after they failed BCG therapy.”

Source: [ClinicalTrials.gov NCT01438112](https://clinicaltrials.gov/study/NCT01438112)

<a id="heading-3.1.5.2"></a>

### 3.1.5.2 Location and Study Date

<a id="topic-3.1.5.2-1"></a>

#### Registered study dates and sites

| Field | Quoted record |
| --- | --- |
| Study start | “2014-03” |
| Primary completion (actual) | “2016-06” |
| Number of sites | “This study has 7 locations” |
| Study chair | “Alex W Yeung, MBBS” |

Source: [ClinicalTrials.gov NCT01438112](https://clinicaltrials.gov/study/NCT01438112)

<a id="heading-3.1.5.3"></a>

### 3.1.5.3 Study Design

<a id="topic-3.1.5.3-1"></a>

#### Registered design: integrated phase 2/3 randomized controlled trial

> “An Integrated Phase II/III, Open Label, Randomized and Controlled Study of the Safety and Efficacy of CG0070 Adenovirus Vector Expressing GM-CSF in Patients With NMIBC With Carcinoma In Situ Disease Who Have Failed BCG”
> “It is therefore, desirable to formulate a protocol to encompass the specialty of this oncolytic vaccine and the unique intravesical delivery to prove the efficacy by a randomized controlled study.”

Source: [ClinicalTrials.gov NCT01438112](https://clinicaltrials.gov/study/NCT01438112)

<a id="topic-3.1.5.3-2"></a>

#### Registered design details

| Field | Quoted record |
| --- | --- |
| Allocation | “Randomized” |
| Interventional model | “Parallel Assignment” |
| Masking | “None (Open Label)” |

Source: [ClinicalTrials.gov NCT01438112](https://clinicaltrials.gov/study/NCT01438112)

<a id="heading-3.1.5.4"></a>

### 3.1.5.4 Eligibility Criteria

<a id="topic-3.1.5.4-1"></a>

#### Inclusion: high-grade disease with carcinoma in situ after BCG

> “Patients must be considered high risk, with pathologically confirmed high grade disease (HG) WHO 2004”
> “Patients must have pathologically-proven unresectable, primary, secondary or concurrent carcinoma in situ disease, defined by having either Ta and/or T1 with CIS, or CIS”
> “Patients must have received at least two or more prior courses of intravesical therapy. BCG must have been one of the prior therapies administered. Patients can have either failed BCG induction therapy within a six month period or have been successfully treated with BCG, but subsequently found to have recurrence.”
> “Residual disease at accrual”
> “Patient to provide a tumor specimen for determination of RB pathway status”

Source: [ClinicalTrials.gov NCT01438112](https://clinicaltrials.gov/study/NCT01438112)

<a id="topic-3.1.5.4-2"></a>

#### Inclusion: cystectomy indicated, age, and performance status

> “Patient need to sign a specific informed consent acknowledging that a delay of cystectomy may lead to an increase chance of progression and/or metastasis with serious or sometimes fatal consequences.”
> “18 years of age or older”
> “Eastern Cooperative Oncology Group (ECOG) performance status <2.”

Source: [ClinicalTrials.gov NCT01438112](https://clinicaltrials.gov/study/NCT01438112)

<a id="topic-3.1.5.4-3"></a>

#### Exclusion criteria

> “Previous systemic chemotherapy or radiation for bladder cancer. Note: Prior immunotherapy or intravesical (administered within the bladder) chemotherapy for superficial disease is acceptable”
> “No bladder cancer residual disease, such as patients that are rendered disease free by TURBT”
> “History of partial cystectomy in the setting of bladder cancer primary tumor.”
> “Concomitant active autoimmune disease (e.g., rheumatoid arthritis, multiple sclerosis, autoimmune thyroid disease, uveitis)”

Source: [ClinicalTrials.gov NCT01438112](https://clinicaltrials.gov/study/NCT01438112)

<a id="heading-3.1.5.5"></a>

### 3.1.5.5 Treatment

<a id="topic-3.1.5.5-1"></a>

#### Experimental arm: CG0070 after DDM pretreatment

> “Interventions: CG0070 oncolytic virus intravesical instillations weekly X6 with each instillation lasting 45 minutes after prior transduction agent of DDM intravesically for 15 minutes”
> “CG0070 adenoviral vector with GM-CSF expression given intravesically 1x10e12 viral particles for each instillations, weekly times six”

Source: [ClinicalTrials.gov NCT01438112](https://clinicaltrials.gov/study/NCT01438112)

<a id="topic-3.1.5.5-2"></a>

#### Control arm: investigator choice of intravesical chemotherapy or interferon

> “Quadruple Choice as interventions”
> “Mitomycin C”
> “Interferon”
> “Valrubicin”
> “Gemcitabine”

Source: [ClinicalTrials.gov NCT01438112](https://clinicaltrials.gov/study/NCT01438112)

<a id="heading-3.1.5.6"></a>

### 3.1.5.6 Study Outcomes

<a id="heading-3.1.5.6.1"></a>

#### 3.1.5.6.1 Rationale for Using Complete Response as the Primary Endpoint

<a id="topic-3.1.5.6.1-1"></a>

##### Registered primary endpoint, phase 2 part: complete response at 9 months

> “Complete Response Proportion (CR)”
> “'CR' Proportion is confirmed by negative biopsy, cystoscopy, cytology weekly times 2 with the first assessment three months after first intravesical treatment and then assessed again at 9 month.”
> “9 months (Phase II)”

Source: [ClinicalTrials.gov NCT01438112](https://clinicaltrials.gov/study/NCT01438112)

<a id="topic-3.1.5.6.1-2"></a>

##### Registered primary endpoint, phase 3 part: durable complete response at 15 months

> “Durable Complete Response Proportion (DCR)”
> “DCR proportion of DCR lasting 12 months or longer will be conducted after a follow up period of 15 months for each patient. The first complete response assessment will be at 3 month.”
> “15 months (Phase III)”

Source: [ClinicalTrials.gov NCT01438112](https://clinicaltrials.gov/study/NCT01438112)

<a id="topic-3.1.5.6.1-3"></a>

##### Registered secondary endpoints

> “Progression rate to muscle invasive disease”
> “Complete Response Survival”
> “The number and percentage of patients experiencing one or more adverse events will be summarized by relationship to study drug, and severity.”
> “Cystectomy Free Survival”

Source: [ClinicalTrials.gov NCT01438112](https://clinicaltrials.gov/study/NCT01438112)

<a id="topic-3.1.5.6.1-4"></a>

##### Regulatory context for durable complete response in single-arm trials

> “attainment of a durable CR may represent clinical benefit by allowing some patients to delay or”
> “forgo radical cystectomy.”

Source: [FDA BCG-unresponsive NMIBC draft guidance (2024)](https://www.fda.gov/media/101468/download)

<a id="heading-3.1.5.7"></a>

### 3.1.5.7 Statistical Analysis Description

<a id="heading-3.1.5.7.1"></a>

#### 3.1.5.7.1 Number of Participants (Planned and Analyzed)

<a id="topic-3.1.5.7.1-1"></a>

##### Registered enrollment

| Field | Quoted record |
| --- | --- |
| Enrollment (actual) | “22” |

Source: [ClinicalTrials.gov NCT01438112](https://clinicaltrials.gov/study/NCT01438112)

<a id="topic-3.1.5.7.1-2"></a>

##### Planned between-arm comparisons

> “The Complete Response Survival time to events of patients who have achieved a complete response at the 3 month assessment will be compared with a log rank test.”
> “The Cystectomy Free Survival time to events of patients will be compared with a log rank test.”

Source: [ClinicalTrials.gov NCT01438112](https://clinicaltrials.gov/study/NCT01438112)

<a id="heading-3.1.5.7.2"></a>

#### 3.1.5.7.2 Description of Analysis Sets

No evidence found.

<a id="heading-3.1.5.8"></a>

### 3.1.5.8 Results

<a id="heading-3.1.5.8.1"></a>

#### 3.1.5.8.1 Participant Disposition

<a id="topic-3.1.5.8.1-1"></a>

##### Study termination

| Field | Quoted record |
| --- | --- |
| Reason for stopping | “Change in study design” |
| Study completion (actual) | “2016-06” |

Source: [ClinicalTrials.gov NCT01438112](https://clinicaltrials.gov/study/NCT01438112)

<a id="heading-3.1.5.8.2"></a>

#### 3.1.5.8.2 Baseline Characteristics

No evidence found.

<a id="heading-3.1.5.8.3"></a>

#### 3.1.5.8.3 Efficacy Results

No evidence found.

<a id="heading-3.1.5.8.4"></a>

#### 3.1.5.8.4 Health-related Quality of Life and Patient-reported Outcomes

No evidence found.

<a id="heading-3.1.5.8.5"></a>

#### 3.1.5.8.5 Safety Results

No evidence found.

<a id="heading-3.1.5.9"></a>

### 3.1.5.9 Study Limitations

<a id="topic-3.1.5.9-1"></a>

#### Summary: limitations of BOND

- BOND was registered as an integrated phase 2/3, open-label, randomized study of CG0070 against investigator choice of mitomycin C, interferon, valrubicin, or gemcitabine in participants with CIS-containing disease after BCG.
- The registry lists the study as terminated for a “Change in study design” with 22 participants enrolled, from March 2014 to June 2016.
- No results posted on ClinicalTrials.gov and no publication or company report of its efficacy or safety results were identified, so the study contributes no efficacy or safety data to this report.
- Eligibility allowed participants who had been “successfully treated with BCG, but subsequently found to have recurrence”, so the registered population differs from the BCG-unresponsive population of BOND-003.

Source: [ClinicalTrials.gov NCT01438112](https://clinicaltrials.gov/study/NCT01438112)

## Related pages
- [Cretostimogene grenadenorepvec (CG0070): BCG-unresponsive high-risk non-muscle-invasive bladder cancer](https://www.evicenter.com/drugs/cretostimogene-grenadenorepvec--bcg-unresponsive-high-risk-non-muscle-invasive-bladder-cancer) · [Markdown](https://www.evicenter.com/drugs/cretostimogene-grenadenorepvec--bcg-unresponsive-high-risk-non-muscle-invasive-bladder-cancer.md)
- [Cretostimogene grenadenorepvec (CG0070) in BCG-unresponsive high-risk non-muscle-invasive bladder cancer: Terms and abbreviations](https://www.evicenter.com/drugs/cretostimogene-grenadenorepvec--bcg-unresponsive-high-risk-non-muscle-invasive-bladder-cancer/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/cretostimogene-grenadenorepvec--bcg-unresponsive-high-risk-non-muscle-invasive-bladder-cancer/terms-and-abbreviations.md)
- [Cretostimogene grenadenorepvec (CG0070): BCG-unresponsive high-risk non-muscle-invasive bladder cancer](https://www.evicenter.com/drugs/cretostimogene-grenadenorepvec--bcg-unresponsive-high-risk-non-muscle-invasive-bladder-cancer/executive-summary) · [Markdown](https://www.evicenter.com/drugs/cretostimogene-grenadenorepvec--bcg-unresponsive-high-risk-non-muscle-invasive-bladder-cancer/executive-summary.md)
- [Cretostimogene grenadenorepvec (CG0070) in BCG-unresponsive high-risk non-muscle-invasive bladder cancer: Product information and disease description](https://www.evicenter.com/drugs/cretostimogene-grenadenorepvec--bcg-unresponsive-high-risk-non-muscle-invasive-bladder-cancer/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/cretostimogene-grenadenorepvec--bcg-unresponsive-high-risk-non-muscle-invasive-bladder-cancer/product-information-and-disease-description.md)
- [Cretostimogene grenadenorepvec (CG0070) in BCG-unresponsive high-risk non-muscle-invasive bladder cancer: Clinical evidence](https://www.evicenter.com/drugs/cretostimogene-grenadenorepvec--bcg-unresponsive-high-risk-non-muscle-invasive-bladder-cancer/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/cretostimogene-grenadenorepvec--bcg-unresponsive-high-risk-non-muscle-invasive-bladder-cancer/clinical-evidence.md)
- [Cretostimogene grenadenorepvec (CG0070) in BCG-unresponsive high-risk non-muscle-invasive bladder cancer: Economic information and modeling report](https://www.evicenter.com/drugs/cretostimogene-grenadenorepvec--bcg-unresponsive-high-risk-non-muscle-invasive-bladder-cancer/economics) · [Markdown](https://www.evicenter.com/drugs/cretostimogene-grenadenorepvec--bcg-unresponsive-high-risk-non-muscle-invasive-bladder-cancer/economics.md)
- [Cretostimogene grenadenorepvec (CG0070) in BCG-unresponsive high-risk non-muscle-invasive bladder cancer: References](https://www.evicenter.com/drugs/cretostimogene-grenadenorepvec--bcg-unresponsive-high-risk-non-muscle-invasive-bladder-cancer/references) · [Markdown](https://www.evicenter.com/drugs/cretostimogene-grenadenorepvec--bcg-unresponsive-high-risk-non-muscle-invasive-bladder-cancer/references.md)
